Biologics Before Surgery Are Not Associated With Postoperative Complications after Surgery for Inflammatory Bowel Disease: A National Surgery Quality Improvement Program Inflammatory Bowel Disease Collaborative Causal Inference Analysis
Preoperative biologic exposure within 60 days of surgery for inflammatory bowel disease was not associated with any causal increase in postoperative adverse outcomes. These findings indicate that biologic before inflammatory bowel disease surgery are safe and do not increase short-term adverse outcomes. See Video Abstract.
Authors
- Randolph M. Steinhagen (ORCID: https://orcid.org/0000-0002-4399-8064)
- N C C I D Collaborative
- Neil H. Hyman
- Tracy L. Hull (ORCID: https://orcid.org/0000-0002-8138-2658)
- Liliana Bordeianou (ORCID: https://orcid.org/0000-0003-3418-6774)
- Tara A. Russell (ORCID: https://orcid.org/0000-0002-3912-3601)
- Nicholas Neel (ORCID: https://orcid.org/0000-0003-0225-762X)
- Samuel Eisenstein (ORCID: https://orcid.org/0000-0002-2646-0625)
- Benjamin L. Cohen
- Stefan D. Holubar
Institutions
- Cleveland Clinic (US)
- University of California, Los Angeles (US)
- UC San Diego Health System (US)
- University of California San Diego (US)
- University of Chicago (US)
- Massachusetts General Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Diseases of the Colon & Rectum
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1097/dcr.0000000000004077
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00